Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK8 | P45983 | 5/20 | 0.51 |
| ▸ | MAPK10 | P53779 | 4/20 | 0.51 |
| ▸ | CCNE1 | P24864 | 13/20 | 0.45 |
| ▸ | CDK2 | P24941 | 13/20 | 0.45 |
| ▸ | CCND1 | P24385 | 9/20 | 0.44 |
| ▸ | CDK6 | Q00534 | 9/20 | 0.44 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.44 |
| ▸ | CDK4 | P11802 | 1/20 | 0.44 |
| ▸ | CDK9 | P50750 | 1/20 | 0.44 |
| ▸ | MAPK9 | P45984 | 3/20 | 0.43 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3667741 | 0.94 | MAPK8 (0.53) | MAPK8MAPK10CCNE1CDK2CCND1 | |
| SCHEMBL3675212 | 0.92 | MAPK8 (0.59) | MAPK8MAPK10CCNE1CDK2CCND1 | |
| SCHEMBL3677279 | 0.92 | MAPK8 (0.51) | MAPK8MAPK10CCNE1CDK2CCND1 | |
| SCHEMBL3669704 | 0.91 | MAPK14 (0.50) | MAPK8CCNE1CDK2CCND1CDK6 | |
| SCHEMBL3669709 | 0.89 | MAPK8 (0.55) | MAPK8MAPK10CCNE1CDK2CCND1 | |
| SCHEMBL3667827 | 0.89 | MAPK8 (0.55) | MAPK8MAPK10CCNE1CDK2CCND1 | |
| SCHEMBL3675431 | 0.89 | MAPK8 (0.55) | MAPK8MAPK10CCNE1CDK2CCND1 | |
| SCHEMBL3679379 | 0.89 | MAPK8 (0.55) | MAPK8MAPK10CCNE1CDK2CCND1 | |
| SCHEMBL3667574 | 0.89 | MAPK8 (0.55) | MAPK8MAPK10CCNE1CDK2CCND1 | |
| SCHEMBL3677941 | 0.89 | MAPK14 (0.48) | MAPK8CCNE1CDK2CCND1CDK6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090221600-A1 | PYRIDO-PYRIDIMIDINE DERIVATIVES USEFUL AS ANTIINFLAMMATORY AGENTS | RANBAXY LABORATORIES LIMITED (IN) | 2009-09-03 | — | — | US | claimed |
| US-20100004215-A1 | COMPOSITIONS OF PHOSPHODIESTERASE TYPE IV INHIBITORS | RANBAXY LABORATORIES LIMITED (IN) | 2010-01-07 | — | — | US | disclosed |
| EP-2111861-A1 | Compositions of phosphodiesterase type IV inhibitors | Ranbaxy Laboratories Limited (IN) | 2009-10-28 | — | — | EP | disclosed |
| US-20090221600-A1 | PYRIDO-PYRIDIMIDINE DERIVATIVES USEFUL AS ANTIINFLAMMATORY AGENTS | RANBAXY LABORATORIES LIMITED (IN) | 2009-09-03 | — | — | US | disclosed |
| US-20090054382-A1 | COMPOSITIONS OF PHOSPHODIESTERASE TYPE IV INHIBITORS | RANBAXY LABORATORIES LIMITED (IN) | 2009-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221600-A1 | PYRIDO-PYRIDIMIDINE DERIVATIVES USEFUL AS ANTIINFLAMMATORY AGENTS | PNPO, TPMT, NOD1 | MAPK8 1902/4885MAPK10 2069/4885CCNE1 863/4885 |
| US-20100004215-A1 | COMPOSITIONS OF PHOSPHODIESTERASE TYPE IV INHIBITORS | PDE4B, PDE4A, PDE3B | MAPK8 60/4885MAPK10 98/4885CCNE1 4327/4885 |
| US-20090054382-A1 | COMPOSITIONS OF PHOSPHODIESTERASE TYPE IV INHIBITORS | PDE4B, PDE4A, PDE3B | MAPK8 62/4885MAPK10 99/4885CCNE1 4312/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.